argenx SE reported $1.24B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
AstraZeneca USD 11.55B 674M Sep/2026
Genmab DKK 748M 77M Jun/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
GRIFOLS EUR 1.65B 101M Sep/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lakefront Biotherapeutics EUR 55.62M 14.56M Jun/2026
Qiagen NV USD 393.64M 17.95M Jun/2026
UCB EUR 2.96B 196M Dec/2025